Issue link: http://osercommunicationsgroup.uberflip.com/i/562595
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 2 5 , 2 0 1 5 4 PRASCO: MOMENTUM CONTINUED With 13 Authorized Generic (AG) prod- ucts launched in 2014, last year was a record one for Prasco in terms of number of new AGs introduced into the market- place. For the five-year period ending in 2014, Prasco launched 42 percent of all Authorized Generics products, with the closest competitor launching 11 percent of new AG products. In 2015, Prasco has managed to build upon that momentum, with four AG products launched in the first half of the year and with four additional Authorized Generics expected to be launched by the end of the year. Prasco's four new Authorized Generics in 2015 brings the company's total number of AG products launched to 70. Prasco Authorized Generics are brand name drugs manufactured under the innovator's New Drug Application (NDA) and sold in the generic market- place under the Prasco label. Prasco's success in the AG category is resultant from what the company calls a complete approach to the pharmaceutical business. At the heart of this complete approach is a partner-centric organiza- tional culture built upon Prasco's Unlimit ® philosophy. This philosophy calls for Prasco to empower its partners by removing – "unlimiting" – barriers that constrain the life- cycles of brand prod- ucts. Extending a product's lifecycle not only gives Prasco's brand partners an opportunity to pro- long the value of their brand name drugs, but also provides pharmacists and patients with a preferable alternative to other generic drugs. Also essential to Prasco's complete approach is that the company has a fully customizable infrastructure that allows Prasco not only to meet the specific needs of a product or partner but also to access the marketplace and thereby MAYNE PHARMA: MORE THAN AN INJECTABLE BUSINESS Isn't Mayne Pharma an injectable busi- ness? No. Well, not anymore. Mayne Pharma's rich history has taken it from a single start-up pharmacy in Australia 170 years ago to a technology-driven global pharmaceutical company, which did pro- duce injectables along the way. Francis Hardey Faulding, an English native and son of a surgeon, migrated to Australia at the age of 26. Three years later, in 1845, Faulding opened a phar- macy. He later purchased another build- ing to house his manufacturing and ware- housing. For 145 years, F. H. Faulding & Co. flourished. In 2001, the Mayne Nickless Group, a provider of healthcare and contract logistics, took over F. H. Faulding as Mayne Group Limited. Then in 2005, Mayne Group Limited. divided the busi- ness into two: Mayne Pharma Limited and Symbion Health Limited. On February 1, 2007, Hospira Inc., an American leading global provider of injectables and infusion technologies, acquired Australia-based Mayne Pharma. At the time, Mayne Pharma was a lead- ing specialty injectable pharmaceutical company. Also in 2007, HalcyGen Pharmaceuticals Ltd., a fellow Australian drug maker, signed a global exclusive license agreement with Mayne Pharma for product development and marketing rights to SUBA ® -Itraconazole, an antifungal agent. As SUBA- Itraconazole moved closer to registration, HalcyGen decided to acquire Mayne Pharma to gain manufacturing and mar- keting rights of the drug. Having built an intellectual property portfolio based on the optimization and delivery of oral dosage forms and acting Continued on Page 85 Continued on Page 85 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Kim Forrester Jules Denton Paul Harris Associate Publishers Lorrie Baumann Editorial Director Jeanie Catron JoEllen Lowry Associate Editors Yasmine Brown Andre Gressieux Graphic Designers Caitlyn Roach Sarah Glenn Customer Service Managers Heather Canale Stacy Davis Savannah Green Tara Neal Show Logistics & Distribution Randal Fisher James Gennette Neil Hicks Sarah Robinson Account Managers Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2015 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy